The Wnt5a/Ror2 noncanonical signaling pathway inhibits canonical Wnt signaling in K562 cells

International Journal of Molecular Medicine

Volumn 27, Issue 1, 2011, Pages 63-69

  Yuan, Yuan ^a   Niu, Chang Chun ^a   Deng, Gang ^a   Li, Zhao Quan ^a   Pan, Jing ^a   Zhao, Chen ^a   Yang, Zong Lin ^a   Si, Wei K E ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

catenin; K562; Leukemia; Ror2; Wnt5a

Indexed keywords

BETA CATENIN; CYCLIN D1; FRIZZLED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; MEMBRANE PROTEIN; PROTEIN ROR2; UNCLASSIFIED DRUG; WNT5A PROTEIN;

ARTICLE; CANCER INHIBITION; CELL NUCLEUS; CELL STRAIN K 562; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INTERNALIZATION; LEUKEMOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RECEPTOR BINDING; SIGNAL TRANSDUCTION; UPREGULATION;

BETA CATENIN; CYCLIN D1; HUMANS; K562 CELLS; LDL-RECEPTOR RELATED PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 78651070815     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2010.560     Document Type: Article

References (36)

1. Logan CY and Nusse R: The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20: 781-810, 2004.
2. KikuchiA, Yamamoto H and Kishida S: Multiplicity of the interactions of Wnt proteins and their receptors. Cell Signal 19: 659-671, 2007.
3. Jenei V, Sherwood V, Howlin J, et al: A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion. Proc Natl Acad Sci USA 106: 19473-19478, 2009.
4. Liu Y, Rubin B, Bodine PV and Billiard J: Wnt5a induces homodimerization and activation of Ror2 receptor tyrosine kinase. J Cell Biochem 105: 497-502, 2008.
5. Oishi I, Suzuki H, Onishi N, et al: The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signaling pathway. Genes Cells 8: 645-654, 2003.
6. Mikels AJ and Nusse R: Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biology 4: e115, 2006.
7. Schambony A and Wedlich D: Wnt-5a/Ror2 regulate expression of XPAPC through an alternative noncanonical signaling pathway. Dev Cell 12:779-792, 2007.
8. O'Connell MP, Fiori JL, Xu M, et al: The orphan tyrosine kinase receptor, ROR2, mediates Wnt5a signaling in metastatic melanoma. Oncogene 29: 34-44, 2010.
9. Jönsson M, Dejmek J, Bendahl PO and Andersson T: Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res 62: 409-416, 2002.
10. Ying J, Li H, Yu J, et al: WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/β-Catenin signaling, and is frequently methylated in colorectal cancer. Clin Cancer Res 14: 55-61, 2008.
11. Kremenevskaja N, von Wasielewski R, Rao AS, et al: Wnt5a has a tumor suppressor activity in thyroid carcinoma. Oncogene 24: 2144-2154, 2005.
12. Roman-Gomeza J, Jimenez-Velascob A, Cordeuc L, et al: WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia. Eur J Cancer 43: 2736-2746, 2007.
13. Liang H, Chen Q, Coles AH, et al: Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell 4: 349-360, 2003.
14. Yuan Y, Li ZQ, Si WK, et al: Correlation between myeloid leukemia development and Wnt5a expression. Acta Academiae Medicinae Militaris Tertiae 29: 2056-2059, 2007.
15. Yuan Y, Si WK, Li ZQ, et al: Differentiation phenotypes of K562 cells induced by exogenous Wnt5a. Zhongguo Shi Yan Xue Ye Xue Za Zhi 15: 946-949, 2007.
16. Da Forno PD, Pringle JH, Hutchinson P, et al: WNT5A expression increases during melanoma progression and correlates with outcome. Clin Cancer Res 14: 5825-5832, 2008.
17. van Amerongen R, Mikels A and Nusse R: Alternative wnt signaling is initiated by distinct receptors. Sci Signal 1: re9, 2008.
18. Hurlstone A and Clevers H: T-cell factors: turn-ons and turnoffs. EMBO J 21: 2303-2311, 2002.
19. He T-C, Sparks AB, Rago C, et al: Identification of c-myc as a target of the APC pathway. Science 281: 1509-1512, 1998.
20. Lin S-Y, Xia W, Wang JC, et al: β-Catenin, a novel prognostic marker for breast cancer:its role in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 97: 4262-4266, 2000.
21. Torisu Y, Watanabe A, Nonaka A, et al: Human homolog of NOTUM, overexpressed in hepatocellular carcinoma, is regulated transcriptionally by beta-catenin/TCF. Cancer Sci 99: 1139-1146, 2008.
22. Austinat M, Dunsch R, Wittekind C, et al: Correlation between β-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma. Mol Cancer 7: 21, 2008.
23. Renard CA, Labalette C, Armengol C, et al: Tbx3 is a downstream target of the Wnt/β-catenin pathway and a critical mediator of β-catenin survival functions in liver cancer. Cancer Res 67: 901-910, 2007.
24. Lustig B, Jerchow B, Sachs M, et al: Negative feedback loop of Wnt signaling through upgulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol 22: 1184-1193, 2002.
25. Ovejero C, Cavard C, Perianin A, et al: Identification of the leukocyte cell-derived chemotaxin 2 as a direct target gene of β-catenin in the liver. Hepatology 40: 167-176, 2004.
26. Yamashita T, Forgues M, Wang W, et al: EpCAM and α-fetoprotein expression defines novel prognostic subtypes of hepacellular carcinoma. Cancer Res 68: 1451-1461, 2008.
27. Niu CC, Si WK, Li J, et al: Effects of stable Wnt5a overexpression on biological characters of K562 cells. Acta Academiae Medicinae Militaris Tertiae 31: 2199-2201, 2009.
28. Harris TJ and Peifer M: Decisions, decisions: β-catenin chooses between adhesion and transcription. Trends Cell Biol 15: 234-237, 2005.
29. Ying J, Li H, Chen YW, et al: WNT5A is epigenetically silenced in hematologic malignancies and inhibits leukemia cell growth as a tumor suppressor. Blood 110: 4130-4131, 2007.
30. Topol L, Jiang X, Choi H, et al: Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent β-catenin degradation. J Cell Biol 162: 899-908, 2003.
31. Nemeth MJ, Topol L, Anderson SM, et al: Wnt5a inhibits canonical Wnt signaling in hematopoietic stem cells and enhances repopulation. Proc Natl Acad Sci USA 104: 15436-15441, 2007.
32. MacLeod RJ, Hayes M and Pacheco I: Wnt5a secretion stimulated by the extracellular calcium-sensing receptor inhibits defective Wnt signaling in colon cancer cells. Am J Physiol Gastrointest Liver Physiol 293: G403-G411, 2007.
33. Green JL, Kuntz SG and Sternberg PW: Ror receptor tyrosine kinases: orphans no more. Trends Cell Biol 18: 536-544, 2008.
34. Sato A, Yamamoto H, Sakane H, et al: Wnt5a regulates distinct signalling pathways by binding to Frizzled2. EMBO J 29: 41-54, 2009.
35. Roszmusz E, Patthy A, Trexler M, et al: Localization of disulfide bonds in the frizzled module of Ror1 receptor tyrosine kinase. J Biol Chem 276: 18485-18490, 2001.
36. Polakis P: The oncogenic activation of beta-catenin. Curr Opin Genet Dev 9: 15-21, 1999.